Australia's CSL buys Novartis influenza vaccine unit for $275 million

October 27
1:20 AM 2014

Australia's CSL Ltd (CSL.AX), the world's largest blood products company, said on Monday it had agreed to buy Novartis AG's (NOVN.VX) global influenza vaccine business for $275 million.

Combining the Novartis unit with CSL subsidiary bioCSL would great the No.2 player in the $4 billion global influenza vaccine industry, CSL said in a statement to the Australian stock exchange.

CSL said it would fund the deal with surplus cash and estimated integration costs at $100 million, while synergies were seen at $75 million a year by 2020.

© 2022 VCPOST, All rights reserved. Do not reproduce without permission.


Join the Conversation

Subscribe to VCpost newsletter

Sign up for our Deals of the Day newsletter.
We will not spam you!

Real Time Analytics